Becton Dickinson and Company
- Industry
- Medical Devices
- Exchange
- US
- Country
- USA
- IPO date
- Jan 1, 1987
- Employees
- 60,000
- Website
- www.bd.com
Composite valuation range · conservative $108–$125 / fair $154–$178 / optimistic $217–$249. At $158.92, Within the fair intrinsic-value range.
At publication $147.63 (May 24, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care
History
Becton, Dickinson and Company (BD) is a medical technology firm that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, with an IPO date of 1987-01-01 and roughly 60,000 employees. After completing the separation of its Waters (Biosciences & Diagnostic Solutions) transaction, BD became a more focused "New BD," and as of the second quarter of fiscal 2026 its continuing operations comprise four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. For the first half of fiscal 2026 (ended March 31, 2026), these segments generated revenue of 3.242 billion, 2.252 billion, 1.019 billion, and 2.687 billion dollars respectively, totaling 9.200 billion dollars. The Waters transaction provided 4 billion dollars in cash, which management allocated as 2 billion dollars to share repurchase and 2 billion dollars to debt repayment, and the company has increased its dividend for 54 consecutive years while retaining an investment-grade credit rating.
Industry position
BD describes itself as one of the world's largest pure-play medical technology companies and states that it holds leading positions in most of the markets it serves. Its revenue base is highly recurring, with the company characterizing itself in 2025 proxy materials as having a consumables revenue structure exceeding 90%, and as of March 31, 2026 certain Medication Management Solutions and Medication Delivery Solutions contracts carried unfulfilled minimum consumables purchase commitments corresponding to roughly 2 billion dollars of future revenue. Its competitive position rests on factual sources including scale and installed base, switching costs (products such as Alaris, Pyxis, monitoring platforms, and pharmacy automation are bound to hospital IT, pharmacy workflows, EMR connectivity, and consumables), channel and compliance barriers requiring long-term certification, registration, clinical validation, and quality management, and high-frequency consumables repurchase. Brands include BD, Vacutainer, Pyxis, and Alaris, and named comparable companies include Thermo Fisher, Medtronic, Boston Scientific, and Baxter. The company also has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing.